NewAmsterdam Pharma Ratios (2021-2026) | NAMS

Ratios Dec2021 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter) -486.94%-2,230.11%-1,602.62%7,233.75%-6,692.86%-1,711.58%-57.19%-721.71%-1,327.30%-90.70%-20,691.09%-234,134.38%-1,593.45%
EBIT Margin (Quarter) -461.85%-2,474.20%-1,685.07%-6,360.40%-3,960.17%-2,306.93%-85.89%-338.47%-2,314.47%-186.13%-15,845.69%-206,187.50%-1,921.71%
EBITDA Margin (Quarter) -461.85%-2,474.20%-1,685.07%-6,360.40%-3,960.17%-2,306.93%-85.89%-338.47%-2,314.47%-186.13%-15,845.69%-206,187.50%-1,921.71%
Operating Margin (Quarter) -461.85%-2,474.20%-1,685.07%-6,360.40%-3,960.17%-2,306.93%-85.89%-338.47%-2,314.47%-186.13%-15,845.69%-206,187.50%-1,921.71%
Net Margin (Quarter) -486.94%-1,602.62%7,233.75%-6,692.86%-1,711.58%-57.18%-721.71%-1,327.30%-90.70%-20,691.09%-234,134.38%-1,593.45%
FCF Margin (Quarter) -369.34%-1,597.59%-4,119.18%-3,924.84%-2,377.71%-43.20%-293.49%-1,225.12%-197.23%-9,428.45%-128,046.88%-1,007.96%
Efficiency
Assets Average (Quarter) 305.37M417.78M467.58M442.94M651.91M841.52M816.76M800.77M777.86M750.96M
Asset Utilization Ratio (Quarter) 0.020.020.080.070.060.080.040.030.03
Leverage & Solvency
Interest Coverage Ratio (Quarter) -0.39-0.20-0.27-0.17-0.23-0.38-0.25-0.17-0.07M-0.18
Times Interest Earned (Quarter) -0.39-0.20-0.27-0.17-0.23-0.38-0.25-0.17-0.07M-0.18
Valuation
Enterprise Value (Quarter) -60.74M-447.38M-441.31M-417.60M-368.31M-340.45M-481.15M-430.71M-422.73M-834.19M-808.48M-739.16M-539.72M-491.32M-458.94M
Return Ratios
Return on Sales (Quarter) -0.05%-0.16%0.72%-0.67%-0.17%-0.01%-0.07%-0.13%-0.01%-2.07%-23.41%-0.16%
Return on Capital Employed (Quarter) -55.47%-49.42%-45.84%-32.35%-23.70%-22.15%-27.33%-32.61%-31.48%
Return on Assets (Quarter) 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%